| Literature DB >> 10683485 |
Z A Martinez1, N D Halim, J L Oostwegel, M A Geyer, N R Swerdlow.
Abstract
NMDA antagonists and dopamine (DA) agonists produce neuropathological and/or behavioral changes in rats that may model specific abnormalities in schizophrenia patients. In adult rats, NMDA antagonists and DA agonists disrupt sensorimotor gating-measured by prepulse inhibition (PPI)-modeling PPI deficits in schizophrenia patients. In addition, high doses of NMDA antagonists produce limbic system pathology that may model neuropathology in schizophrenia patients. We examined these behavioral and neuropathological models across development in rats. Both the NMDA antagonist phencyclidine (PCP) and the DA agonist apomorphine disrupted PPI in 16 day pups, demonstrating early developmental functionality in substrates regulating these drug effects on PPI. In contrast, PCP neurotoxicity was evident only in adult rats. Brain mechanisms responsible for the PCP disruption of PPI, and PCP-induced neurotoxicity, are dissociable across development.Entities:
Mesh：
Substances：
Year: 2000 PMID： 10683485 DOI： 10.1016/s0091-3057(99)00217-8
Source DB: PubMed Journal: Pharmacol Biochem Behav ISSN： 0091-3057 Impact factor: 3.533